In this latest episode from VJOncology, join us as we explore the latest news in mesothelioma research with three distinguished speakers. Anthony Chalmers, MD, University of Glasgow, Glasgow, UK, Dean Fennell, MBBS, PhD, FRCP, University Hospitals of Leicester NHS Trust, Leicester, UK, and Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, UK. Discover the Phase II SYSTEMS-2 trial’s potential to reshape mesothelioma treatment and revolutionize patient care, unravel the excitement surrounding targeted therapy, particularly the TEAD inhibitor IK-930, showing great promise in disrupting cancer-promoting pathways, and finally learn more about the crucial role of immunotherapy in combating mesothelioma and its potential to offer new avenues for improved patient outcomes.